Finding the Money: Where to Look and What Sells
Thursday June 13th from 11:45am-1:00pm
There’s money available for new and cash hungry private companies who know where to look and bring the right investment proposition, but it’s not going to be easy or quick. Get the scoop on who is investing or re-investing, how much is available, and where is the money being allocated. Recent venture funds, with a few notable exceptions, are closing well below $300 million. Which begs the question, how are life science funds investing differently today? Gain insider’s perspective from an LP who is facing the realities of a diminishing percentage of total capital to invest in life sciences venture funds. Take a deep dive with leading corporate venture funds and the venture capital firms who have raised new funds over the past 24 months, and looking critically at so many great ideas, including yours.
Daniel G. Kleeburg, Partner, Assurance and Advisory Business Services, Ernst & Young LLP
Simeon George, SR One
David Kabakoff, Executive Partner, Soffinova Ventures
Rachel Leheny, Managing Director and Founder, Valence Life
Garth Timoll, Principal, Top Tier Capital
Funding collaborations between pharmaceutical companies and traditional venture capital funds
Thursday June 13th from 4:15pm-5:30pm
Big Pharma and biotech companies are collaborating with traditional venture capital firms in new and ambitious models. This panel will look at the underpinnings of these new funding strategies and associated investment trends. How and when are we seeing these collaborations formed? Do they really work? And who are the beneficiaries? Join leading industry and institutional venture investor partners in a lively discussion of their core and evolving collaborations.
Julia Vax, Partner, Arnold & Porter LLP
Robert Adelman, co-Founder and Managing Partner, Venbio
Hubert Birner, Managing Partner, TVM|Capital
Pearl S. Huang, VP, Global Head of DPAc, GlaxoSmithKline
Jim Scopa, Managing Director, MPM Capital
Rounding Up the Successes: Angels, Institutional Investors and Crossing Over
Friday June 14th from 10:00am-11:15am
Competition for private financing is steep, the timelines can be unpredictably long and valuations are tough but these companies have gotten it done. Whatever round is looming large – Angel, Series A, mezzanine or that one round that puts your company on the map – learn from the CEOs who have run the gauntlet. Join us for a dynamic and frank discussion on the private rounds that are getting done and learn more about deal structures, terms and valuations from the CEOS who have recently raised rounds have hopefully positioned themselves to go back for more.
Mark Goldsmith, Partner, Third Rock Ventures
Karen Boezi, CEO, Redwood Biosciences
John K. Celebi, Chief Business Officer, Igenica, Inc.
Faheem Hasnain, President and CEO, Receptos
Willie Quinn, President & CEO, Bullet Biotechnology, Inc.
Back Doors and Front Doors: Alternative Entrances to the Public Markets
Friday June 14th from 1:45pm-3:00pm
While IPOs remain the favored approach for many, a surprising number of companies are looking hard at their best approach to the public markets — from the Form 10 self-filing process and repurposing of public shells to reverse mergers and the advantages offered by the JOBs act ruling. What’s clear is that you need to have all options on the table, and be prepared to evaluate the complexities, expense, timelines and the prospects for stability in the aftermarket. By June, what will this landscape and the preferred deals look like? Hear lessons and war stories from experienced management, and gain perspective from legal counsel, investors and banking on recent legislation, SEC interactions, deal structure.
Bryan Giraudo, Managing Director, Leerink Swann
Georgia Erbez, CFO, Raptor Pharmaceuticals
Alan Fuhrman, Ambit Biosciences
Rachel Leheny, Managing Director and Founder, Valence Life Sciences
Scott Stanton, Morrison & Foerster